Drugs / THE-0504
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07646106 | Nov 2024 → May 2027 expected | colorectal carcinoma, gastric cancer, pancreatic adenocarcinoma, small cell lung carcinoma +1 | Thena Biotech S.r.l. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THE-0504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07646106 ↗ |
| Route | Intravenous | “administered intravenously” NCT07646106 ↗ |